UCLA Invents Newsletter
Newsletter published by: UCLA OIP-ISR March 2015





April 03, 2015
FirstFridays @ OIP
Topic:  "Blackstone Launchpad Program at UCLA"
Speaker:  Deanna Evans, Executive Director, Entrepreneurial Programs

March 10, 2015
3rd Annual UCLA Medical Device Industry Partnering Conference

More Events


Merganser Biotech logo

UCLA Licensee Merganser Biotech Raises $28 Million
Merganser Biotech Inc. announced that the company has raised $28 million in a Series A financing round. The round was led by the Novartis Venture Fund, and will be used to develop hepcidin mimetic peptides as therapeutics for the treatment of rare hematological and iron overload diseases.
Flexlogix logo

UCLA Engineering Alumni Launch Startup Flex Logix
The startup launches from stealth mode with founders receiving the prestigious Lewis Award for outstanding paper at ISSCC. Led by founding Rambus CEO Geoff Tate, Flex Logix is backed by Series A financing led by Lux Capital.
nanotech image

UCLA Nanodrug Technology Optimizes Cancer Therapy
UCLA scientists have developed a revolutionary approach that brings together traditional drugs and nanotechnology-enhanced medications to create safer and more effective treatments.
Med Device Event Logo

3rd Annual UCLA Medical Device Industry Partnering Conference
UCLA's 3rd Annual Medical Device Industry Partnering Conference provides a unique opportunity for UCLA inventors, investors, and industry executives to establish new relationships for furthering innovation. The event features industry panels, startup pitches, and provides ample time for networking.

Intellectual Property Announcements

New U.S. Patents Awarded

  • 8,969,521 - General method for designing self-assembling protein nanomaterials  | T. Yeates, et al.
  • 8,966,660 - Methods and systems of digital rights management for integrated circuits  | M. Potkonjak, et al.
  • 8,962,569 - Compositions comprising SPP24 peptide fragments  | J. Wang, et al.
  • 8,956,825 - Intranuclear protein transduction through a nucleoside salvage pathway  | R. Weisbart
  • 8,951,754 - Methods and materials for making simvastatin and related compounds  | Y. Tang, et al.
  • 8,951,740 - Genotoxicity as a biomarker for inflammation  | R. Schiestl, et al.
  • 8,947,123 - Wave dynamic differential logic  | I. Verbauwhede, et al.


New UCLA Technologies Available for Licensing

Life Sciences
Physical Sciences



    Previous Issue - UCLA Invents
    • UCLA Licensee CohBar, Inc. Completes $11.25M IPO
    • FDA Considers Kythera’s ATX-101 for Chin Fat Treatment
    • NeuroInDx Unveils New Product Based on UCLA IP
    • UCLA Anderson Embraces Tech Industry, Entrepreneurs
    UCLA TechMatch Program for
    Startups and Established Companies

    Customized, automated service matches UCLA innovation with
    industry research and technology licensing interests.  Subscribe today.

    UCLA Invents Newsletter, Vol. 3, No. 7

    How to Subscribe

    Send editorial comments and corrections to:  
    Bob Nidever,  bnidever@research.ucla.edu

    Contributors: Neil Bajpayee, Tara Kamin

    UCLA Invents is published by the UCLA Office of Intellectual Property & Industry Sponsored Research
    11000 Kinross Ave., Suite 200 | Los Angeles, CA 90095 | tel. 310-794-0558 | http://oip.ucla.edu

    Copyright © 2014 The Regents of the University of California. All Rights Reserved.

    Share this